Greatbatch submits PMA for spinal cord stim
Greatbatch files a pre-market approval application for its spinal cord neuromodulation system for treatment of chronic pain of the trunk and limbs.
Greatbatch this week filed a pre-market approval application with the FDA for its spinal cord neuromodulation system.
The neuromodulation system comes from the Frisco, Texas-based company's subsidiary, QiG Group, which hopes to win indication to treat chronic pain of the trunk and limbs.
This FDA bid is a part of the company's "strategic evolution of its product offerings to include the development of complete medical device systems in order to raise the growth and profitability" of the company, Greatbatch said in a regulatory filing.